[Osteoporosis in cancer survivors].
The detection of late sequelae in survivors of cancer has become increasingly important as developments in diagnostic and therapeutic methods have led to a more and long-term survival rates in tumoral patients. Osteoporosis is one of such problem that has been increasingly identified in patients with cancer. Significant bone loss and increased risk of fractures have been described in these patients. Medical problems associated with the malignancy or caused by the oncologic treatment are the main factors involved in bone loss. Therefore, patients at risk for bone loss should be undergo preventive or therapeutic interventions at an early enough stage to prevent fractures.
Olmos Martínez
José Manuel
JM
Departamento de Medicina Interna. Hospital Universitario Marqués de Valdecilla. Universidad de Cantabria. Santander. Cantabria. España. miromj@humv.es
González Macías
Jesús
J
D000367:Age Factors; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000150:complications; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control / Q000532:radiotherapy; D006801:Humans; D007006:Hypogonadism / Q000150:complications; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000532:radiotherapy; D010024:Osteoporosis / Q000139:chemically induced / Q000150:complications / Q000209:etiology*; D011471:Prostatic Neoplasms / Q000150:complications; D011878:Radiotherapy / Q000009:adverse effects; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D012189:Retrospective Studies; D012307:Risk Factors
D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents; D020849:Raloxifene Hydrochloride